EMV Capital advises on a restructuring and investment in Vortex Biotech Holdings. Appointment of new Vortex CEO to drive growth.
London, UK, 16[th] August 2022 – International venture capital investor and adviser, EMV Capital Ltd (EMV Capital), is pleased to announce that it has advised on the restructuring and investment in Vortex Biotech Holdings, a leader in the oncology liquid biopsy market. The company also appointed industry veteran Paul Jones to drive growth.EMV Capital advised Deeptech Disruptive Growth Investments (Deeptech) on its acquisition of Vortex, Inc. in 2019 for £113,000, following c.$30m of previous investments taking its sophisticated liquid biopsy platform to first sales. Since then, EMV Capital